Description

Overview

How do Calcichew-D3 Chewable Tablets biologically regulate bone mineralisation? Calcichew-D3 Chewable Tablets are designed to address the dual physiological requirement for bone health: the provision of structural substrate (calcium) and the hormonal regulation of its absorption (vitamin D3). Calcium carbonate, the primary active ingredient, dissociates in the acidic environment of the stomach to release elemental calcium ions. These ions are critical for the mineralisation of the collagen matrix in bone tissue, providing rigidity and strength. Simultaneously, the cholecalciferol (vitamin D3) in Calcichew-D3 Chewable Tablets undergoes hydroxylation in the liver to form 25-hydroxycholecalciferol, and subsequently in the kidneys to form the biologically active hormone 1,25-dihydroxycholecalciferol (calcitriol). This active metabolite binds to vitamin D receptors in the small intestine, significantly increasing the efficiency of active calcium transport across the intestinal wall. Without sufficient vitamin D3, the body absorbs less than 15% of dietary calcium; Calcichew-D3 Chewable Tablets restore this mechanism to ensure adequate serum calcium levels are maintained without the body needing to leach calcium from the skeleton.

What is the impact of Calcichew-D3 Chewable Tablets on Parathyroid Hormone (PTH)? A key pharmacological goal of Calcichew-D3 Chewable Tablets is the suppression of secondary hyperparathyroidism. When serum calcium levels drop (hypocalcaemia), the parathyroid glands secrete Parathyroid Hormone (PTH). PTH acts to restore blood calcium levels by stimulating osteoclasts cells that break down bone tissue to release stored calcium back into the bloodstream. By providing a steady exogenous supply of calcium and ensuring its absorption via vitamin D3, Calcichew-D3 Chewable Tablets maintain stable serum calcium. This triggers a negative feedback loop that reduces PTH secretion, thereby inhibiting osteoclast activity and reducing the rate of bone resorption (bone loss), which is particularly critical in conditions like osteoporosis.

Why are Isomalt and Sucrose included? Calcichew-D3 Chewable Tablets are formulated with specific excipients to improve palatability and compliance, which is vital for long-term supplementation. The formulation includes sucrose and isomalt (E953) as sweetening and bulking agents. While these improve the taste and texture of the chewable tablet, their presence is biologically significant for patients with metabolic intolerances. Specifically, the inclusion of sucrose provides immediate sweetness, while isomalt adds bulk and a sugar-like texture without the same caloric spike, although it may have mild laxative effects in sensitive individuals. The tablets also contain povidone as a binder and magnesium stearate as a lubricant to ensure the tablet holds its shape but breaks down effectively upon chewing.

Understanding Osteoporosis and Osteomalacia Calcichew-D3 Chewable Tablets are clinically indicated for conditions defined by compromised bone density. Osteoporosis is a systemic skeletal disease characterised by low bone mass and micro-architectural deterioration of bone tissue, leading to consequent increase in bone fragility and susceptibility to fracture. This is often driven by the “calcium gap” where dietary intake fails to meet metabolic loss. In the elderly, skin synthesis of vitamin D declines, further exacerbating this deficit. Calcichew-D3 Chewable Tablets are also used in the treatment of osteomalacia (softening of the bones due to defective mineralisation), serving as a direct replenishment therapy to correct the severe deficiencies that lead to skeletal pain and muscle weakness.

Who Is It For

Who are Calcichew-D3 Chewable Tablets suitable for? Calcichew-D3 Chewable Tablets are suitable for adults and the elderly. They are specifically designed for individuals with a diagnosed calcium and vitamin D deficiency, or those at high risk of such deficiencies, such as housebound patients with limited exposure to sunlight. Calcichew-D3 Chewable Tablets are an ideal choice for patients receiving specific treatment for osteoporosis (e.g., bisphosphonates) who require adjunct supplementation to ensure the efficacy of their primary therapy. Calcichew-D3 Chewable Tablets are suitable for use during pregnancy and breastfeeding to meet the increased calcium demands of the mother and foetus, provided the daily intake does not exceed medical recommendations.

Usage Instructions

How to take Calcichew-D3 Chewable Tablets correctly? Calcichew-D3 Chewable Tablets are for oral use.

Administration: The tablets can be chewed or sucked; they should not be swallowed whole. This aids the initial mechanical breakdown of the calcium carbonate, preparing it for dissolution in the stomach acid.

Dosage (Adults and Elderly): The typical recommended dose is one tablet taken twice daily.

Dosage (Prevention of Deficiency): For simple prevention of deficiency, the dose may be adjusted by a doctor.

Timing: Taking Calcichew-D3 Chewable Tablets with meals can help maximise calcium absorption due to the increased secretion of stomach acid, although they can be taken with or without food.

What should be avoided when taking Calcichew-D3 Chewable Tablets? Users should strictly avoid taking Calcichew-D3 Chewable Tablets simultaneously with certain foods or medicines that inhibit absorption. Foods high in oxalic acid (like spinach and rhubarb) and phytic acid (like whole cereals) can reduce calcium absorption. Furthermore, Calcichew-D3 Chewable Tablets should not be taken within 2 hours of eating iron supplements or taking antibiotics like tetracyclines or quinolones, as calcium can bind to these drugs and prevent them from working.

Warnings

When must Calcichew-D3 Chewable Tablets not be used? Calcichew-D3 Chewable Tablets must not be used by patients with severe renal impairment (kidney failure), as the damaged kidneys cannot properly metabolise the calcium or the vitamin D, leading to dangerous accumulation. They are contraindicated in patients with hypercalcaemia (abnormally high levels of calcium in the blood) or hypercalciuria (excessive calcium in the urine), as adding more calcium would be hazardous. Calcichew-D3 Chewable Tablets must not be used by individuals with nephrolithiasis (kidney stones) or calcium deposits in the kidneys (nephrocalcinosis). Patients with hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take Calcichew-D3 Chewable Tablets due to the sucrose and isomalt content.

Alternatives

Common alternatives to Calcichew-D3 Chewable Tablets? If Calcichew-D3 Chewable Tablets are not suitable due to taste, texture, or dietary restrictions, common alternatives include:

Adcal-D3 Chewable Tablets: A very similar combination of calcium carbonate and vitamin D3, often used as a direct substitute but with different flavouring agents (fruit).

Calceos Chewable Tablets: Another combined calcium and vitamin D supplement that provides similar therapeutic benefits for osteoporosis management.

Accrete D3 Film-Coated Tablets: Suitable for patients who dislike the texture of chewable tablets and prefer a tablet that can be swallowed whole.

Thezalin (Calcium & Vitamin D3) Capsules: A capsule format for those who cannot tolerate chewable chalky textures.

Invita D3: A pure vitamin D supplement (without calcium), suitable for patients who have sufficient dietary calcium intake but require vitamin D correction specifically.